Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Darolutamide for non-metastatic, castration-resistant prostate cancer.

Burki T.

Lancet Oncol. 2019 Mar;20(3):e139. doi: 10.1016/S1470-2045(19)30102-0. Epub 2019 Feb 21. No abstract available.

PMID:
30799257
2.

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Fizazi K, Smith MR, Tombal B.

Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24. Review.

3.

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1063-1072. doi: 10.1007/s00280-017-3417-3. Epub 2017 Aug 11. Erratum in: Cancer Chemother Pharmacol. 2017 Oct 23;:.

4.

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME.

Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.

PMID:
28851578
5.

Darolutamide (ODM-201) for the treatment of prostate cancer.

Shore ND.

Expert Opin Pharmacother. 2017 Jun;18(9):945-952. doi: 10.1080/14656566.2017.1329820. Epub 2017 May 24. Review.

PMID:
28490267
6.

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1073-1077. doi: 10.1007/s00280-017-3433-3. No abstract available.

PMID:
29063294
7.

Darolutamide Slows Metastasis in Prostate Cancer.

[No authors listed]

Cancer Discov. 2019 Apr;9(4):OF6. doi: 10.1158/2159-8290.CD-NB2019-029. Epub 2019 Mar 1.

PMID:
30824428
8.

Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.

Holmstrom S, Naidoo S, Turnbull J, Hawryluk E, Paty J, Morlock R.

Patient. 2019 Feb;12(1):57-67. doi: 10.1007/s40271-018-0349-x.

PMID:
30519830
9.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
10.

Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?

Konac E, Kiliccioglu I, Sogutdelen E, Dikmen AU, Albayrak G, Bilen CY.

Exp Biol Med (Maywood). 2017 Dec;242(18):1795-1801. doi: 10.1177/1535370217728499. Epub 2017 Aug 24.

11.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

12.

AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.

Todenhöfer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN.

J Urol. 2017 Jan;197(1):135-142. doi: 10.1016/j.juro.2016.06.094. Epub 2016 Jul 17.

PMID:
27436429
13.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
14.

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.

Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.

Virchows Arch. 2012 Aug;461(2):157-62. doi: 10.1007/s00428-012-1270-7. Epub 2012 Jul 6.

PMID:
22767266
15.

Enzalutamide for patients with metastatic castration-resistant prostate cancer.

Ramadan WH, Kabbara WK, Al Basiouni Al Masri HS.

Onco Targets Ther. 2015 Apr 17;8:871-6. doi: 10.2147/OTT.S80488. eCollection 2015. Review.

16.

A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.

Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.

PMID:
25981621
17.

Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other.

Alanazi IO, Al Shehri ZS, Ebrahimie E, Giahi H, Mohammadi-Dehcheshmeh M.

Mol Carcinog. 2019 Jan 15. doi: 10.1002/mc.22975. [Epub ahead of print]

PMID:
30644608
18.

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.

PMID:
29033099
19.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators.

Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18.

PMID:
25701170
20.

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.

Kwak C, Wu TT, Lee HM, Wu HC, Hong SJ, Ou YC, Byun SS, Rhim HY, Kheoh T, Wan Y, Yeh H, Yu MK, Kim CS.

Int J Urol. 2014 Dec;21(12):1239-44. doi: 10.1111/iju.12589. Epub 2014 Aug 6.

Supplemental Content

Support Center